Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 314 participants.

Also called NCT01709513

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 314 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01709513
Other papers using this trial's data
  • Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial Journal of clinical lipidology, 2020 DOI, PubMed 32192644
  • Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial Journal of clinical lipidology, 2015 DOI, PubMed 26687696

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Canada, France, Israel, Italy, Norway, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01709513. Randomized; quadruple masking; primary purpose treatment. Start 2012-09-30 (actual); primary completion 2014-05-31 (actual). Results posted on 2015-08-28.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
Condition
Hypercholesterolemia
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Ezetimibe
Intervention (Drug)
Alirocumab
Intervention (Drug)
Placebo
Lead sponsor
Regeneron Pharmaceuticals (class: industry)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01709513
Content hash
da8b4cd989c7744a719ac84cebee76d870f164e035e247558cb271f89c4522b2